Hummingbird Bioscience to Collaborate with Merck on Clinical Trial of Anti-VISTA Antibody HMBD-002 in Combination with KEYTRUDA® (Pembrolizumab) for Treatment of Cancer
|
By IntellAsia: Resources
on 10/25/2021
HOUSTON and SINGAPORE, Oct. 25, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targe...
Full "IntellAsia: Resources" article
|
|